Updating the role played by immunotherapy for allergic rhinitis: meta-analysis

Basit Öğe Kaydı
dc.contributor.authorCingi, Cemal
dc.contributor.authorMuluk, Nuray Bayar
dc.contributor.authorHanci, Deniz
dc.contributor.authorUlusoy, Seckin
dc.contributor.authorSahin, Fezan
dc.date.accessioned2020-06-25T18:15:43Z
dc.date.available2020-06-25T18:15:43Z
dc.date.issued2015
dc.departmentKırıkkale Üniversitesi
dc.description.abstractBackgroundAlthough the effectiveness of allergen monotherapy immunotherapy for allergic rhinitis (AR) has been well established by many prior studies, other aspects of immunotherapy are still incompletely documented by high-quality studies. The many published papers describe various results. The aim of the present study was to conduct a meta-analysis on the effectiveness of allergen immunotherapy. MethodsA total of 56 homogeneous studies were included in the analysis. The inclusion criteria used to select articles were as follows: (1) placebo-controlled clinical trials; (2) the use of immunotherapy; (3) participants and/or physicians were or were not blinded to immunotherapy or placebo assignment (single-blinding, double-blinding, or no-blinding studies); and (4) randomization or not of those in the immunotherapy and placebo groups. ResultsBetween 2003 and 2013, 114 placebo-controlled clinical trials were reported in Medline. Studies describing recovery rates in immunotherapy and placebo groups numbered 56. The distribution of such works was homogeneous (heterogeneity chi-square = 16.11; degrees of freedom [df] = 55; p = 1.000). The extent of recovery in immunotherapy groups was 53.671-fold greater than in placebo groups (Mantel-Haenszel [M-H] pooled risk ratio [RR] = 53.671; 95% confidence interval [CI], 36.981 to 77.893; z = 20.96; p < 0.001). ConclusionOur meta-analysis suggests that immunotherapy is associated with a recovery rate 53.671-fold that of placebo.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1002/alr.21447
dc.identifier.endpage142en_US
dc.identifier.issn2042-6976
dc.identifier.issn2042-6984
dc.identifier.issue2en_US
dc.identifier.pmid25424754
dc.identifier.scopus2-s2.0-84922566538
dc.identifier.scopusqualityQ1
dc.identifier.startpage132en_US
dc.identifier.urihttps://doi.org/10.1002/alr.21447
dc.identifier.urihttps://hdl.handle.net/20.500.12587/6234
dc.identifier.volume5en_US
dc.identifier.wosWOS:000348915400007
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWileyen_US
dc.relation.ispartofInternational Forum Of Allergy & Rhinology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectmeta-analysisen_US
dc.subjectimmunotherapyen_US
dc.subjectallergic rhinitisen_US
dc.subjectplacebo-controlled clinical trialsen_US
dc.subjectrecovery rateen_US
dc.titleUpdating the role played by immunotherapy for allergic rhinitis: meta-analysisen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Updating the role played by immunotherapy for allergic rhinitis meta-analysis.pdf
Boyut:
806.19 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu